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Background. Tuberculosis remains a huge public health problem and the prolonged treatment duration obstructs effective 
tuberculosis control. Higher rifampicin doses have been associated with better bactericidal activity, but optimal dosing is uncertain. 
This analysis aimed to characterize the relationship between rifampicin plasma exposure and treatment response over 6 months in a 
recent study investigating the potential for treatment shortening with high-dose rifampicin.
Methods. Data were analyzed from 336 patients with pulmonary tuberculosis (97 with pharmacokinetic data) treated with 
rifampicin doses of 10, 20, or 35 mg/kg. The response measure was time to stable sputum culture conversion (TSCC). We derived 
individual exposure metrics with a previously developed population pharmacokinetic model of rifampicin. TSCC was modeled 
using a parametric time-to-event approach, and a sequential exposure-response analysis was performed.
Results. Higher rifampicin exposures increased the probability of early culture conversion. No maximal limit of the effect was 
detected within the observed range. The expected proportion of patients with stable culture conversion on liquid medium at week 
8 was predicted to increase from 39% (95% confidence interval, 37%–41%) to 55% (49%–61%), with the rifampicin area under the 
curve increasing from 20 to 175 mg/L·h (representative for 10 and 35 mg/kg, respectively). Other predictors of TSCC were baseline 
bacterial load, proportion of culture results unavailable, and substitution of ethambutol for either moxifloxacin or SQ109.
Conclusions. Increasing rifampicin exposure shortened TSCC, and the effect did not plateau, indicating that doses >35 mg/kg 
could be yet more effective. Optimizing rifampicin dosage while preventing toxicity is a clinical priority.
Keywords. high-dose rifampicin; pharmacometrics; PK-PD; exposure-response; sputum culture conversion.
As the leading infectious disease killer, tuberculosis remains 
a huge public health concern [1]. The efficacy of available 
tuberculosis therapy is limited, in part, by the long duration of 
treatment, which is an obstacle to effective tuberculosis con-
trol. Effective, safe, and shorter treatment regimens are needed 
to make meaningful progress toward eliminating tuberculosis 
globally.
Rifampicin is a key drug in the first-line regimen, and has 
together with pyrazinamide enabled treatment shortening in 
the past. The choice of the currently recommended rifampicin 
dose (10 mg/kg) was not based on optimal efficacy but rather 
driven by cost and fear of toxic effects [2]. Murine tuberculo-
sis models suggest that the bactericidal and sterilizing effect of 
rifampicin can be enhanced by increased doses, resulting in sig-
nificant treatment shortening [3–6]. In patients with tuberculo-
sis, doses up to 40 mg/kg daily were safe and well tolerated over 
14 days [7, 8], and a model-based analysis demonstrated that 
higher rifampicin concentrations could increase the bacteri-
cidal activity during the first treatment week significantly [9]. 
The potential for tuberculosis treatment shortening using high-
dose rifampicin was recently studied in a multiarm, multistage 
trial, also evaluating substitution of ethambutol with either 
moxifloxacin or SQ109 [10]. Moxifloxacin produces a more 
rapid initial decline in bacterial load compared to the standard 
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treatment [11]. The candidate drug SQ109 has a novel mecha-
nism of action and is well tolerated [12]. The primary end point 
was time to stable sputum culture conversion (TSCC), based on 
liquid cultures until week 12.
A central theorem in clinical pharmacology states that it is the 
unbound concentration of the active compound(s) at the site of 
action that drives the effect. Hence, it is of primary interest to 
describe the relationship between individual drug exposure and 
response, rather than simply correlate study arm to outcome 
[10]. Given that exposure observations from the site of action 
are difficult or impossible to obtain, plasma concentrations are 
often used as a proxy. Population pharmacokinetic models are 
powerful tools to capture both the median drug exposure and 
the variability within a population, and to detect and charac-
terize covariate relationships. Individual exposures can subse-
quently be linked to models describing the outcome, in this case 
TSCC. Survival-type outcome data as this can be characterized 
with time-to-event-analysis using parametric hazard models 
[13]. Compared with Cox regression [14], well-fitting paramet-
ric models are expected to yield higher statistical power and 
do not necessarily rely on proportionality assumptions [15]. 
Furthermore, parametric models allow for easy testing of non-
linear covariate-relationships and enable simulations to predict 
outcomes in different scenarios.
In this article, we describe the population pharmacokinetics 
of rifampicin, and quantify for the first time the link between 
rifampicin exposure and treatment response in the multiarm, 
multistage study, using an innovative model-based approach 
simultaneously accounting for other predictors. With the devel-
oped model, we simulated the expected outcome over a range 
of rifampicin exposures to assess the potential for treatment 
shortening.
METHODS
Study Design and Data
The study design and enrollment criteria were described in 
detail in the original publication [10]. In short, this multicenter 
study included patients newly diagnosed pulmonary tubercu-
losis from 7 sites in Tanzania and South Africa. Patients were 
randomized to either the control arm or 1 of 4 experimental 
arms in a ratio of 2:1:1:1:1; regimens are described in Table 1. 
Drug concentrations were assessed at day 28 in 20 patients 
per arm, consecutively enrolled from 2 South African and 2 
Tanzanian sites. The morning dose was administered after 
light breakfast, and blood sampling was conducted within 30 
minutes before and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours after 
the dose. Rifampicin plasma concentrations were determined 
with a validated ultraperformance liquid chromatography 
method (accuracy, 95.1%–102.4%; intraday and interday pre-
cision, <4.2%l lower limit of quantification, 0.13 mg/L).
Sputum samples were collected at the start of treatment, 
weekly until week 8, and again at weeks 10, 12, 14, 17, 22, and 26. 
Sputum samples were cultured in mycobacterial growth incu-
bator tubes (MGIT960; Becton Dickinson) and on Löwenstein-
Jensen medium. TSCC was defined as the time from the start of 
treatment to the first of 2 consecutive negative cultures.
Pharmacokinetic Modeling
Nonlinear mixed-effects modeling was used to describe 
rifampicin pharmacokinetics, estimating both the typi-
cal parameter values and the random variability. A  pub-
lished model, developed using data from rifampicin doses 
of 10–40 mg/kg, was used as a starting point [8]. Given that 
the pharmacokinetic sampling was conducted 4 weeks after 
treatment initiation, rifampicin autoinduction was assumed 
to be completed [8]. Model fit was assessed with goodness-
of-fit plots, including visual predictive checks, and the Akaike 
information criterion. The investigated covariates were body 
weight, fat-free mass [16], sex, country, human immunodefi-
ciency virus status, and the presence of lung cavitation. The 
decision on inclusion in the final model was based on statis-
tical significance (P < .05) and biological plausibility. Results 
were compared with those of a previously published noncom-
partmental analysis (NCA) [10].
Table 1. Regimens and Doses for the 5 Study Armsa 
Arm
Regimen (Once-Daily Administration)b
Duration, moRifampicin Dose, mg/kg Isoniazid Dose, mg/kg Pyrazinamide Dose, mg/kg 4th Drug (Dose)
Control arm 10 5 25c Ethambutol (15–20 mg/kg)c 6
Experimental arms
 1 35 5 25 Ethambutol (15–20 mg/kg) 3d
 2 10 5 25 SQ109 (300 mg) 3d
 3 20 5 25 SQ109 (300 mg) 3d
 4 20 5 25 Moxifloxacin (400 mg) 3d
aPharmacokinetic sampling was conducted in 20 patients per arm.
bAdapted in 4 weight bands: 30–37, 38–54, 55–70, and >70 kg. 
cPyrazinamide and ethambutol were included only for the first 2 months.
dAfter 3 months with experimental regimens, all patients received another 3 months of standard continuation-phase treatment (rifampicin, 10 mg/kg; isoniazid, 5 mg/kg). 
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Pharmacodynamic Modeling
The response variable was TSCC, derived separately based on 
liquid and solid culture results. Both variables were modeled 
using a time-to-event approach, but the liquid culture TSCC 
was the primary focus. Different parametric hazard distribu-
tions determining TSCC were evaluated, including constant, 
Weibull, and surge functions. In the selected base model, the 
covariates evaluated included baseline bacterial load (time to 
positivity in liquid medium), sex, body weight, country, study 
site, and lung damage (radiographic scoring and presence of 
cavitation [17]). Because TSCC may be affected by missing 
or contaminated sputum samples, a metric to account for this 
(percentage of unavailable culture results until last planned 
visit or before dropout) was therefore derived and evaluated. 
The same criteria for covariate inclusion were applied as for the 
pharmacokinetic analysis, and the same methods of evaluating 
model fit.
Exposure-Response Analysis
Treatment-related covariates were investigated in a sequential 
exposure-response analysis. The influence of rifampicin expos-
ure in plasma (area under the curve from 0 to 24 hours after 
dose [AUC0–24h], or maximal concentration [Cmax] derived using 
the final population pharmacokinetic model) was tested using 
linear, power, and maximal effect  (Emax)  models. In addition, 
the choice of fourth drug (ethambutol, moxifloxacin, or SQ109) 
and the influence of pyrazinamide and isoniazid exposure (pub-
lished NCA-derived AUC0–24h or Cmax [10]) were investigated.
Because pharmacokinetic information was obtained in a sub-
set of the patients, individual exposure metrics were missing for 
about 75% of the patients. To enable analysis of the whole popu-
lation and use information on rifampicin dose and demograph-
ics, we applied imputation methods. Individual rifampicin 
exposures were predicted using the developed population phar-
macokinetic model, the administered dose, and relevant patient 
characteristics. Adequacy of the imputation was evaluated in 
the patients with pharmacokinetic data available by comparing 
imputed and observed metrics. Selection of parameter-covari-
ate relationships were performed with single imputation, and all 
included covariates were reevaluated for statistical significance 
with backward deletion. The final parameter values and their 
uncertainty were derived after multiple imputation (n  =  100) 
using Rubin’s rules [18, 19]. For pyrazinamide and isoniazid, 
the pharmacokinetic metrics were imputed to the median per 
absolute dose of the corresponding NCA-derived variable in the 
subset of patients with pharmacokinetic observations.
Simulations of Clinical Impact
To evaluate the impact of included covariates, secondary out-
come metrics, such as median TSCC and conversion rates at 
week 8 and 12, were simulated under a number of scenarios, 
varying a single covariate at a time. A  data set with 10 000 
virtual tuberculosis patients formed the basis for the simu-
lations. The population was created by sampling from covar-
iate distributions mimicking those observed in the study (see 
Supplementary Material).
Software
All software used is described in the Supplementary Material.
RESULTS
Patients and Data
In total, 365 patients were included in the study. Two patients 
with drug resistance were excluded, leaving 363 patients in 
this analysis. Of the 100 patients planned for pharmacokinetic 
measurements, rifampicin results were available for 97. Detailed 
demographics of the population have been described elsewhere 
[10]; patient characteristics important to our analyses are listed 
in Table 2.
From the 97 patients, there were in total 956 measurements 
of rifampicin plasma concentrations available. Predose samples 
were excluded from the model fitting owing to missing dose his-
tory, as were 24 samples with suspected erroneous time record-
ings, resulting in 845 observations, of which 654 were above the 
limit of quantification.
Of the 363 patients included in the pharmacodynamic ana-
lysis, 296 reached stable culture conversion within 26 weeks. 
Among the patients not reaching conversion, 32 of 67 patients 
dropped out before the end of the study or lacked a culture 
result from the week 26 visit and were censored in the time-to-
event analysis at the time of their last recorded culture result. 
For liquid cultures, the median proportion of results unavaila-
ble per patient was 17% (range, 0%–76%), and the proportions 
differed substantially between study sites.
Pharmacokinetic Modeling
The previously developed population pharmacokinetic model 
fitted the data adequately. Details on model structure, modifi-
cations from the original, parameter estimates and model evalu-
ation are presented in the Supplementary Material and Figure S1. 
Evaluations showed that the model could well predict individual 
exposures (AUC0–24h) derived from NCA (Figures  1A and S2) 
and generated plausible individual exposure distributions for the 
multiple imputation procedure (Figure 1B).
Pharmacodynamic Modeling
The best base hazard model for TSCC derived from liquid cul-
tures was a surge function defined by amplitude, peak time, and 
peak width (Akaike information criterion, 3053; compared with 
3231 and 3162 for constant and Weibull hazard, respectively; 
see also Supplementary Figure S3). The covariates found to 
be statistically significant were baseline bacterial load and the 
percentage of unavailable culture results. The latter explained 
a marked difference in TSCC between study sites, caused 
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Figure 1. Evaluation of the pharmacokinetic model. A, Comparison between individual rifampicin area under the concentrations curve from 0 to 24 hours after the dose 
(AUC0–24h) at day 28 derived by noncompartmental analysis (NCA) and by the model, per rifampicin dose level (circles represent 10 mg/kg; triangles, 20 mg/kg; squares, 35 mg/
kg). B, Distribution of AUC0–24h values (box-and-whisker plots) simulated including interindividual variability for 9 representative patients (dose level 10 mg/kg for individuals 
1–3, 20 mg/kg for individuals 4–6, and 35 mg/kg for individuals 7–9) with corresponding individual typical AUC0–24h, that is, expected value given the individual’s dose and 
fat-free mass (FFM), and “true” AUC0–24h, that is, expected value given the individual’s rifampicin dose, FFM and observed rifampicin plasma concentrations. The 9 patients 
were chosen to cover the 3 most common absolute rifampicin doses per dose level, simply selecting the first included patient per dose. Boxes represents the first, second, 
and third quartiles, and whiskers extend to the highest and lowest values within 1.5 times the interquartile range. Abbreviation: PK, pharmacokinetics.
Table 2. Patient Characteristics Important for Pharmacokinetic and Pharmacodynamic Modeling
Patient Characteristic
Population Included in Analysis
PK Analysis (n = 97) PD Analysis (n = 363)
Age, median (range), y 34 (18–56) 33 (18–86)
Weight, median (range), kg 54 (35–80) 53 (35–86)
Fat-free mass, median (range), kga 44.7 (28.8–55.9)b 44.6 (28.8–61.0)b
Female sex, No. (%) 29 (30) 107 (29)
HIV infection, No. (%) 2 (2) 24 (7)
Time to positivity in mycobacterial growth incubator tube 
at baseline, median (range), dc
4.3 (0.54–17.1)d 4.4 (0.54–21.7)e
Lung cavitation present at baseline, No. (%) 50 (76)f 176 (70)g
Radiographic score at baseline, median (range)h 60 (3–113)f 58 (3–113)g
Abbreviations: HIV, human immunodeficiency virus; PD, pharmacodynamic; PK, pharmacokinetic.
aEvaluated only in the PK model and calculated from body weight, height, and sex according to the formula described by Janmahasatian et al [16]. 
bData missing in 1 patient. 
cEvaluated only in the PD model. 
dData missing in 2 patients. 
eData missing in 6 patients. 
fData missing in 31 patients. 
gData missing in 111 patients.
hDefined as percentage of lung affected plus 40 if cavitation is present, as described by Ralph et al [17]. 
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by varying levels of missing data. Further details and results 
for TSCC derived from solid cultures are described in the 
Supplementary Material.
Exposure-Response Analysis
Individual rifampicin exposures were found to significantly 
affect the hazard (AUC0–24h to a greater extent than Cmax), with a 
high exposure leading to an increased probability of early spu-
tum culture conversion (SCC). A sigmoid relationship did not 
describe the data better than a linear relationship; therefore, 
a maximal effect could not be reliably estimated. The choice 
of fourth drug with the applied dose had an additional statis-
tically significant effect, with moxifloxacin decreasing TSCC 
and SQ109 increasing TSCC compared with ethambutol. An 
effect of pyrazinamide exposure (AUC0–24h or Cmax) was only 
statistically significant in univariate analysis, and this was not 
included in the final model. No effect of isoniazid exposure 
was detected.
The detailed parameterization of the covariate-parameter 
relationships, statistical significance for each included covar-
iate, final parameter values, and the model code are included 
in the Supplementary Material. The final model’s good descrip-
tion of the observed data is demonstrated in Figure 2. The haz-
ard-function per study arm is shown in Supplementary Figure 
S4. Results for TSCC derived from solid cultures were similar 
(see Supplementary Material).
Simulations of Clinical Impact
TSCC was shortened with increased rifampicin exposure, as 
demonstrated in Figure 3, showing the expected TSCC profiles 
in a virtual population having rifampicin exposure equal to 
the median exposures observed in the 10-, 20-, and 35-mg/kg 
groups. Figure 4 shows the expected increase in proportion of 
patients with SCC at week 8, with increasing rifampicin expo-
sures for the same virtual population, for example, from 39% 
(95% confidence interval, 37%–41%) to 55% (49%–61%), with 
rifampicin AUC0–24h increasing from 20 to 175 mg/L·h (repre-
sentative of 10 and 35  mg/kg, respectively). For a population 
without any missing culture results, the corresponding values 
would range from 54% (95% confidence interval, 52%–56%) to 
72% (65%–78%) (Supplementary Figure S5). The substantial 
shortening effect on TSCC caused by low baseline bacterial load 
is depicted in Supplementary Figure S6, and Supplementary 
Figure S7 shows the impact of substituting ethambutol for 
either SQ109 or moxifloxacin.
DISCUSSION
In this pioneering analysis we linked individual plasma expo-
sures of the key drug rifampicin to TSCC, a commonly used 
end point in phase II tuberculosis studies. Higher rifampicin 
exposure during the first 3 months of treatment was shown to 
shorten TSCC for patients with pulmonary tuberculosis. The 
Figure 2. Evaluation of the final time-to-event model describing time to sputum culture conversion (TSCC) based on liquid cultures, per study arm, in the form of a visual 
predictive check. Solid lines represent Kaplan-Meier curves based on the observed data. Vertical tick marks signify censored data, and shaded area outlines 95% prediction 
interval based on simulations using the model. Study arms include the control arms (R10HZE) and experimental arms 1–4 (R35HZE, R10HZQ, R20HZQ and, R20HZM). (Number 
in arm name represent rifampicin dose [in milligrams per kilogram] used in the first treatment period, 2 months for R10HZE and 3 months for all other arms). Abbreviation: 
SCC, sputum culture conversion.
Downloaded from https://academic.oup.com/cid/article-abstract/67/1/34/4948255
by St Andrews University Library user
on 27 June 2018
Rifampicin Exposure and Treatment Response • CID 2018:67 (1 July) • 39
Rifampicin Exposure and Treatment Response
relationship between rifampicin exposure and TSCC was sta-
tistically significant for both liquid and solid cultures. No max-
imal effect of rifampicin could be derived within the observed 
range, indicating that doses even higher than 35  mg/kg may 
yield additional benefit, if they can be safely and practically 
administered. However, the modest magnitude of the impact on 
SCC predicted for very high rifampicin exposures (Figure 4 and 
Supplementary Figure S3) suggests that increased rifampicin 
doses may on its own be insufficient for shortening treatment 
more than to 4 months.
The original analysis of this study only included between-reg-
imen comparisons [10], whereas our model-based analysis 
could also detect the impact of individual compounds. Patients 
receiving SQ109 instead of ethambutol actually had a lower 
probability of culture conversion, predicted to delay SCC 1 week 
for a typical patient given 10 mg/kg of rifampicin. It remains 
unclear whether SQ109 exposure levels were sufficiently high 
(pharmacokinetic data not yet available); a potential interaction 
with rifampicin may have affected exposure levels. However, 
we infer that it is unlikely that SQ109 applied in the studied 
dose could play a role in shortening of tuberculosis treatment. 
Substitution with moxifloxacin was predicted to typically gen-
erate a 1-week-shorter TSCC. This agrees with previous results 
[11, 20, 21].
The large effect of baseline bacterial load has been docu-
mented in previous studies [22–24], and it is physiologically 
plausible that a larger bacterial burden takes longer to be 
cleared. The impact of missing culture results was also expected. 
Missing culture results due to unavailable samples or contam-
ination will intrinsically delay conversion and must therefore 
be taken into account in any analysis. The pragmatic approach 
taken here was to introduce a covariate quantifying the pro-
portion of missing culture results per patient. Better still than 
accounting for missing culture results would be to avoid having 
them, for example, by performing multiple cultures per time 
point [25], or by using novel methods to quantify mycobacteria, 
Figure 4. Expected proportion of patients with sputum culture conversion (SCC) at week 8 over varying rifampicin exposures for a virtual population of patients (distribution 
of baseline bacterial load and missing sputum samples mimicking that of the study) treated with standard doses of isoniazid, pyrazinamide, and ethambutol. Black dots repre-
sents simulation results (n = 10 000 in each); dark gray line, a locally weighted smooth of the simulation results; and light gray shaded area, 95% confidence interval based on the 
uncertainty in the estimate of the parameter for rifampicin effect. Vertical lines represent median observed exposures in the dose groups 10 (red), 20 (green), and 35 (blue) mg/kg, 
respectively, and tick marks at the bottom of the graph are individual observed exposures. Abbreviation: AUC0–24h, area under the curve from 0 to 24 hours after dose.
Figure 3. Predicted proportion without sputum culture conversion (SCC) versus 
time after start of treatment for virtual populations of patients (n = 10 000) having 
rifampicin area under the concentration versus time curve from 0 to 24 hours after 
the dose (AUC0-24h) of either 21, 62, or 173 mg/L·h (median observed exposure in 
dose groups 10, 20 and 35 mg/kg, respectively), and standard doses of isoniazid, 
pyrazinamide, and ethambutol. The distribution of baseline bacterial load and miss-
ing sputum samples in the simulation mimicked the results in the study used to 
build the models.
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such as the molecular bacterial load assay [26]. This assay is a 
polymerase chain reaction–based method and as such is not 
sensitive to contamination. It generates results faster, beneficial 
especially for adaptive study designs, but it has not been evalu-
ated against clinical outcomes to date.
In other work based partly on the same data, higher pyrazi-
namide exposure has been suggested to shorten TSCC [27]. In 
our analysis, individual pyrazinamide exposure was a statisti-
cally significant predictor for TSCC only when baseline bacter-
ial load was not controlled for. A limitation was the simplistic 
imputation of exposure in patients lacking pharmacokinetic 
data based on the typical observed pyrazinamide exposure 
per dose. However, given the modest interindividual variabil-
ity in pyrazinamide pharmacokinetics [28], the imputation is 
expected to perform reasonably well. No link between isonia-
zid exposure and TSCC could be identified. The lack of a sta-
tistically significant relationship should not be interpreted as a 
demonstration of that higher exposures do not yield additional 
benefits; it may instead be an effect of limited power.
Time-to-event analysis with parametric hazard models 
has several advantages over classic Cox regression, and it has 
recently been used in a similar analysis focused on rifapentine 
[29]. The constant proportionality of hazards, a necessary con-
dition in Cox regression, is difficult to fulfill for complex phar-
macological exposure-response relationships and time-varying 
effects [30]. The statistical power is generally higher with a para-
metric hazard model than with nonparametric approaches [31]. 
Furthermore, the developed model can be used to predict out-
comes of future trials, something that is imperative in the deci-
sion-making process moving novel antituberculosis regimens 
forward, and for clinical trials simulations optimizing study 
designs. On the other hand, parametric models are better only 
when they describe the true underlying hazard distribution 
well, which we have ensured with stringent model evaluation.
The current analysis has some limitations. The evaluated out-
come parameter, TSCC, is an intermediate marker substituting 
for the actual clinical end point in tuberculosis treatment, which 
is relapse-free cure. Although TSCC and month 2 SCC have 
been used as primary end points in recent phase II trials lead-
ing to accelerated and conditional regulatory approval [32, 33] 
and have been linked to relapse rate [34], there is no clear evi-
dence of the predictive performance of such metrics in correlat-
ing with the clinical end point [35]. 
The phase III study of shorter moxifloxacin-containing regi-
mens failed to demonstrate noninferiority for relapse-free cure 
compared to standard of care, even though the median TSCC 
was significantly shorter in the experimental arms [11]. A poten-
tial reason for the lack of sterilizing activity of the moxifloxa-
cin-containing regimens may be the inability of this drug to 
penetrate into tuberculosis lesions where persistent mycobacte-
ria can reside [36]. Rifampicin, on the other hand, penetrates 
well into tuberculosis lesions and is known to be effective against 
persistent and intracellular bacteria and to drive prevention of 
relapse in animal models [5, 37–39]. Therefore, we postulate that 
the shorter TSCC seen with higher rifampicin exposure trans-
lates to a higher frequency of relapse-free cure, but this must be 
confirmed in clinical trials. The scope of this analysis did not 
include an exposure-toxicity component; earlier work found no 
link between rifampicin dose and adverse events [7, 10].
Limitations of the final model’s simulation properties origi-
nate from the nonlinear relationships in the pharmacokinetic 
model and the linear exposure-response relation without a 
maximum effect. Both properties make simulations of doses 
and exposures far outside the observed range more uncertain. 
Furthermore, only just over a quarter of the patients had indi-
vidual rifampicin concentrations observed. This shortcoming 
was partly mitigated by application of a multiple imputation 
procedure, enabling us to keep all patients with outcome data 
in the analysis and expected to provide better estimate of 
parameter uncertainty than single imputation [40]. Finally, the 
pharmacokinetic model was validated only internally, no free 
rifampicin concentrations were measured, and the potential 
contribution of rifampicin’s less active 25-desacetyl metabolite 
was not considered.
In conclusion, with a model-based exposure-response ana-
lysis, we were able to link increasing rifampicin exposure to 
modestly shorter TSCC. A crucial new finding was that max-
imal effect of rifampicin was not reached, indicating that the 
optimal dose from an efficacy standpoint could be higher than 
35 mg/kg. A safety assessment of 50 mg/kg is already ongoing 
in the extension of the HIGHRIF1 study [7]. Presupposing new 
tablet formulations to manage pill burden, we suggest that high-
dose rifampicin could be an important component of a short-
ened tuberculosis regimen, simplifying therapy for patients 
and management of treatment programs. The most appropriate 
rifampicin dose, balancing efficacy and safety aspects, remains 
to be defined and should be further studied in well-designed 
and sufficiently powered clinical trials.
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